Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Hood River Capital Management LLC

Hood River Capital Management LLC lessened its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 4.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,070,980 shares of the medical equipment provider's stock after selling 51,085 shares during the quarter. Lantheus comprises about 1.8% of Hood River Capital Management LLC's investment portfolio, making the stock its 12th biggest position. Hood River Capital Management LLC owned about 1.55% of Lantheus worth $85,989,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC boosted its position in Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 208 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Lantheus by 161.4% during the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 247 shares during the last quarter. Principal Securities Inc. acquired a new stake in shares of Lantheus during the fourth quarter worth $28,000. Fidelis Capital Partners LLC purchased a new stake in shares of Lantheus in the first quarter valued at $34,000. Finally, Nkcfo LLC acquired a new position in Lantheus in the second quarter valued at $47,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Stock Up 1.2 %

NASDAQ LNTH traded up $1.31 on Monday, reaching $111.36. The company had a trading volume of 583,068 shares, compared to its average volume of 1,018,083. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The firm has a 50-day moving average of $105.51 and a 200-day moving average of $84.39. The firm has a market capitalization of $7.72 billion, a PE ratio of 16.80 and a beta of 0.50.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The firm had revenue of $394.10 million during the quarter, compared to analysts' expectations of $382.12 million. During the same quarter last year, the company posted $1.40 earnings per share. Lantheus's revenue for the quarter was up 22.5% compared to the same quarter last year. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Insider Activity

In related news, Director Gary J. Pruden sold 12,530 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the completion of the transaction, the director now owns 11,978 shares of the company's stock, valued at $1,138,389.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Lantheus news, Director Gary J. Pruden sold 12,530 shares of the company's stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the transaction, the director now directly owns 11,978 shares of the company's stock, valued at approximately $1,138,389.12. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Andrea Sabens sold 341 shares of the firm's stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the sale, the chief accounting officer now directly owns 62,216 shares of the company's stock, valued at approximately $7,661,900.40. The disclosure for this sale can be found here. Insiders sold 40,852 shares of company stock worth $3,922,001 over the last ninety days. Corporate insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have commented on LNTH shares. Truist Financial lowered their price target on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. B. Riley upped their price objective on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. JMP Securities cut their target price on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 1st. Redburn Atlantic started coverage on Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price target for the company. Finally, Leerink Partners raised their price objective on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a report on Thursday, July 11th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.